Last reviewed · How we verify
Lidex (FLUOCINONIDE)
Lidex (Fluocinonide) is a corticosteroid medication that targets the glucocorticoid receptor to reduce inflammation. Originally developed and currently owned by Alvogen, it has been FDA-approved since 1971 for various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. As an off-patent medication, Lidex is available from multiple generic manufacturers. Key safety considerations include potential skin thinning and increased risk of infections. Lidex is a small molecule corticosteroid that works by binding to the glucocorticoid receptor, leading to anti-inflammatory effects.
At a glance
| Generic name | FLUOCINONIDE |
|---|---|
| Sponsor | Alvogen |
| Drug class | Corticosteroid [EPC] |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Inflammatory dermatosis
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- Burning
- Itching
- Irritation
- Dryness
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
- Perioral dermatitis
- Allergic contact dermatitis
- Maceration of the skin
- Secondary infection
Key clinical trials
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. (PHASE4)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- Cutaneous Lupus Medication Experience Study
- Impact of Fluocinonide 0,05% in Oral Lichen Planus (NA)
- Improvement of Psoriasis Patients' Adherence to Topical Drugs (NA)
- Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma (NA)
- Using an Internet Study to Improve Adherence for Psoriasis Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |